![]() ![]() Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gilead’s portfolio. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. ![]() (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. FOSTER CITY, Calif.-( BUSINESS WIRE)-Gilead Sciences, Inc. ![]()
0 Comments
Leave a Reply. |